BOSTON, May 03, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the Company granted stock options to new employees to purchase shares of the Company’s common stock, pursuant…Read More
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635c4
